The most recent trading session ended with AngioDynamics (ANGO - Free Report) standing at $5.37, reflecting a -0.74% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily loss of 0.65%. Meanwhile, the Dow experienced a drop of 0.49%, and the technology-dominated Nasdaq saw a decrease of 0.96%.
The medical device maker's stock has dropped by 12.32% in the past month, falling short of the Medical sector's gain of 1.98% and the S&P 500's gain of 3.27%.
The upcoming earnings release of AngioDynamics will be of great interest to investors. The company is expected to report EPS of -$0.14, down 366.67% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $76.71 million, down 4.96% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.43 per share and revenue of $316.15 million, which would represent changes of -616.67% and -6.67%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for AngioDynamics. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 10.9% lower within the past month. AngioDynamics is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 56, placing it within the top 23% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.2% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
The most recent trading session ended with AngioDynamics (ANGO - Free Report) standing at $5.37, reflecting a -0.74% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily loss of 0.65%. Meanwhile, the Dow experienced a drop of 0.49%, and the technology-dominated Nasdaq saw a decrease of 0.96%.
The medical device maker's stock has dropped by 12.32% in the past month, falling short of the Medical sector's gain of 1.98% and the S&P 500's gain of 3.27%.
The upcoming earnings release of AngioDynamics will be of great interest to investors. The company is expected to report EPS of -$0.14, down 366.67% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $76.71 million, down 4.96% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.43 per share and revenue of $316.15 million, which would represent changes of -616.67% and -6.67%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for AngioDynamics. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 10.9% lower within the past month. AngioDynamics is holding a Zacks Rank of #3 (Hold) right now.
The Medical - Instruments industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 56, placing it within the top 23% of over 250 industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.2% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Get the latest research report on ANGO - FREE